Antibodies to watch in 2022

MAbs

14, 2014296

DOI: 10.1080/19420862.2021.2014296

Citation Report

#	Article	IF	Citations
2	Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy. Biochemical and Biophysical Research Communications, 2022, 599, 31-37.	2.1	13
3	Engineering redox sensors into CHO cells enables nearâ€realâ€time quantification of intracellular redox in bioprocesses. Biotechnology and Bioengineering, 2022, , .	3.3	2
4	Biopharmaceutical Manufacturing: Historical Perspectives and Future Directions. Annual Review of Chemical and Biomolecular Engineering, 2022, 13, 141-165.	6.8	19
5	Poloxamer 188 as surfactant in biological formulations â€“ An alternative for polysorbate 20/80?. International Journal of Pharmaceutics, 2022, 620, 121706.	5.2	34
6	Upstream cell culture process characterization and in-process control strategy development at pandemic speed. MAbs, 2022, 14, 2060724.	5.2	9
7	Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab. Frontiers in Chemistry, 2022, 10, 826923.	3.6	0
8	MALDI-TOF-MS-Based Identification of Monoclonal Murine Anti-SARS-CoV-2 Antibodies within One Hour. Antibodies, 2022, 11, 27.	2.5	3
9	The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 581-583.	0.9	0
10	Current Approaches to Monitor Macromolecules Directly from the Cerebral Interstitial Fluid. Pharmaceutics, 2022, 14, 1051.	4.5	7
11	Approved anti-PD-1 monoclonal antibodies in China: A bridge too far for US approval. European Journal of Cancer, 2022, 169, 103-105.	2.8	5
12	Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?. Pharmaceuticals, 2022, 15, 616.	3.8	7
13	Development of a stable antibody production system utilizing an Hspa5 promoter in CHO cells. Scientific Reports, 2022, 12, .	3.3	3
14	Conformational Entropy as a Potential Liability of Computationally Designed Antibodies. Biomolecules, 2022, 12, 718.	4.0	8
16	Recent Advances and Challenges in Uveal Melanoma Immunotherapy. Cancers, 2022, 14, 3094.	3.7	23
17	Antibody drug conjugates: The dos and don'ts in clinical development. , 2022, 240, 108235.		7
18	A Fully-Human Antibody Specifically Targeting a Membrane-Bound Fragment of CADM1 Potentiates the T Cell-Mediated Death of Human Small-Cell Lung Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 6895.	4.1	5
19	The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant. Current Issues in Molecular Biology, 2022, 44, 2842-2855.	2.4	1
20	Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies. Frontiers in Immunology, 0, 13, .	4.8	24

#	Article	IF	Citations
21	Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Science Immunology, 2022, 7, .	11.9	18
22	3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations. Antibodies, 2022, 11, 46.	2.5	3
23	Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery. Briefings in Bioinformatics, 2022, 23, .	6.5	29
24	Monoclonal antibody therapies against SARS-CoV-2. Lancet Infectious Diseases, The, 2022, 22, e311-e326.	9.1	114
25	Antibodyâ€“drug conjugates: What drives their progress?. Drug Discovery Today, 2022, 27, 103311.	6.4	9
26	Differentiation and verification of monoclonal antibody therapeutics by integrating accurate mass analyses at intact, subunit and subdomain levels for forensic investigation. Forensic Chemistry, 2022, 30, 100434.	2.8	1
27	FcÎ³RIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. Cell Reports, 2022, 40, 111099.	6.4	9
28	Designing antibodies as therapeutics. Cell, 2022, 185, 2789-2805.	28.9	65
29	Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron. Cell Research, 2022, 32, 831-842.	12.0	16
30	Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation. MAbs, 2022, 14, .	5.2	9
32	Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges. Drug Design, Development and Therapy, 0, Volume 16, 2639-2657.	4.3	9
33	Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro Functionality. Antibodies, 2022, 11, 54.	2.5	1
34	In vitro/in vivo degradation analysis of trastuzumab by combining specific capture on HER2 mimotope peptide modified material and LC-QTOF-MS. Analytica Chimica Acta, 2022, 1225, 340199.	5.4	4
35	Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteins. Journal of Pharmaceutical and Biomedical Analysis, 2022, 220, 115018.	2.8	3
36	Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review. Biology, 2022, 11, 1308.	2.8	6
37	A trimeric immunoglobin Gâ€binding domain outperforms recombinant protein G and protein L as a ligand for fragment antigenâ€binding purification. Journal of Chromatography A, 2022, 1681, 463464.	3.7	1
38	Changes in antibody binding and functionality after humanizing a murine scFv anti-IFN-Î±2: From in silico studies to experimental analysis. Molecular Immunology, 2022, 151, 193-203.	2.2	0
39	Expediting the chromatographic analysis of COVID-19 antibody therapeutics with ultra-short columns, retention modeling and automated method development. Journal of Pharmaceutical and Biomedical Analysis, 2022, 221, 115039.	2.8	8

#	Article	IF	Citations
40	A protein identification method for proteomics using amino acid composition analysis with IoT-based remote control. Analytical Biochemistry, 2022, 657, 114904.	2.4	0
41	Dual-target Bridging ELISA for Bispecific Antibodies. Bio-protocol, 2022, 12, .	0.4	3
42	All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading. Chemical Science, 2022, 13, 8781-8790.	7.4	10
43	Alternative Routes of Administration for Therapeutic Antibodiesâ€"State of the Art. Antibodies, 2022, 11, 56.	2.5	14
44	Comparison of hydrophobicity scales for predicting biophysical properties of antibodies. Frontiers in Molecular Biosciences, 0, 9, .	3.5	14
45	Mechanism of Proteinâ€"PDMS Visible Particles Formation in Liquid Vial Monoclonal Antibody Formulation. Journal of Pharmaceutical Sciences, 2022, , .	3.3	0
46	Single Domain Antibody application in bacterial infection diagnosis and neutralization. Frontiers in Immunology, 0, 13, .	4.8	9
47	Antibodies as Snakebite Antivenoms: Past and Future. Toxins, 2022, 14, 606.	3.4	8
48	NIR-PIT: Will it become a standard cancer treatment?. Frontiers in Oncology, 0, 12, .	2.8	1
49	The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity. International Journal of Molecular Sciences, 2022, 23, 11325.	4.1	6
50	The industry of therapeutic monoclonal antibodies in Brazil: Public policies as instruments of technology upgrading. Science and Public Policy, 2023, 50, 42-58.	2.4	1
51	A critical overview of current progress for COVID-19: development of vaccines, antiviralÂdrugs, and therapeutic antibodies. Journal of Biomedical Science, 2022, 29, .	7.0	64
53	Non-clinical safety evaluations of next-generation therapeutic antibodies. Folia Pharmacologica Japonica, 2022, 157, 458-463.	0.2	0
54	A Review of Potential Therapeutic Strategies for COVID-19. Viruses, 2022, 14, 2346.	3.3	3
55	Molecular Dynamics Simulation of the Antigenâ€"Antibody Complex Formation Process between Hen Egg-White Lysozyme and HyHEL-10. Bulletin of the Chemical Society of Japan, 2022, 95, 1611-1619.	3.2	2
56	Clinical Aspects of B Cell Immunodeficiencies: The Past, the Present and the Future. Cells, 2022, 11, 3353.	4.1	4
57	Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection. International Journal of Molecular Sciences, 2022, 23, 12754.	4.1	3
60	Neutropenia in Cynomolgus Monkeys With Anti-Drug Antibodies Associated With Administration of Afucosylated Humanized Monoclonal Antibodies. Toxicologic Pathology, 0, , 019262332211315.	1.8	1

#	Article	IF	Citations
61	Engineering the supernatural: monoclonal antibodies for challenging infectious diseases. Current Opinion in Biotechnology, 2022, 78, 102818.	6.6	2
62	Non-specificity as the sticky problem in therapeutic antibody development. Nature Reviews Chemistry, 2022, 6, 844-861.	30.2	23
63	Structural Investigation of Therapeutic Antibodies Using Hydroxyl Radical Protein Footprinting Methods. Antibodies, 2022, 11, 71.	2.5	8
64	Fragment-based computational design of antibodies targeting structured epitopes. Science Advances, 2022, 8, .	10.3	14
66	A multivalent antibody assembled from different building blocks using tag/catcher systems: A case study. Protein Engineering, Design and Selection, 0, , .	2.1	0
67	SILAC-based quantitative proteomics and microscopy analysis of cancer cells treated with the N-glycolyl GM3-specific anti-tumor antibody 14F7. Frontiers in Immunology, 0, 13, .	4.8	1
68	Neutrophils as immune effector cells in antibody therapy in cancer. Immunological Reviews, 2023, 314, 280-301.	6.0	12
69	Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma. Pharmaceutics, 2022, 14, 2494.	4.5	0
70	Improvement of monoclonal antibody stability by modulating trace metal iron concentration in cell culture media: A case study. Process Biochemistry, 2023, 125, 130-140.	3.7	1
71	Automated assembly of hybrid dynamic models for CHO cell culture processes. Biochemical Engineering Journal, 2023, 191, 108763.	3.6	2
72	Expression, purification, and study on the efficiency of a new potent recombinant scFv antibody against the SARS-CoV-2 spike RBD in E. coli BL21. Protein Expression and Purification, 2023, 203, 106210.	1.3	2
73	Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations. BioDrugs, 2023, 37, 99-108.	4.6	3
74	Development of therapeutic antibodies for the treatment of diseases. Molecular Biomedicine, 2022, 3, .	4.4	19
75	Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab. MAbs, 2023, 15, .	5.2	3
76	Antibodies to watch in 2023. MAbs, 2023, 15, .	5.2	103
77	Rapidly accelerated development of neutralizing COVIDâ€19 antibodies by reducing cell line and CMC development timelines. Biotechnology and Bioengineering, 0, , .	3.3	8
79	A potential antibody repertoire diversification mechanism through tyrosine sulfation for biotherapeutics engineering and production. Frontiers in Immunology, 0, 13, .	4.8	1
80	Unambiguous Identification of Glucose-Induced Glycation in mAbs and other Proteins by NMR Spectroscopy. Pharmaceutical Research, 2023, 40, 1341-1353.	3.5	4

#	Article	IF	Citations
81	Enhanced antibody-defucosylation capability of Î±-L-fucosidase by proximity-based protein fusion. Biochemical and Biophysical Research Communications, 2023, 645, 40-46.	2.1	2
82	Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. Medical Review, 2023, 2, 555-569.	1.2	6
83	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0
85	CD3 Target Affinity Chromatography Mass Spectrometry as a New Tool for Functionâ€“Structure Characterization of T-Cell Engaging Bispecific Antibody Proteoforms and Product-Related Variants. Analytical Chemistry, 2023, 95, 2260-2268.	6.5	2
86	Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert Opinion on Drug Discovery, 2023, 18, 231-245.	5.0	4
87	Isomer analysis by mass spectrometry in clinical science. TrAC - Trends in Analytical Chemistry, 2023, 159, 116907.	11.4	0
88	Development of an Antibody Delivery Method for Cancer Treatment by Combining Ultrasound with Therapeutic Antibody-Modified Nanobubbles Using Fc-Binding Polypeptide. Pharmaceutics, 2023, 15, 130.	4.5	1
89	Advances in Antibody-Based Therapeutics for Cerebral Ischemia. Pharmaceutics, 2023, 15, 145.	4.5	1
90	Cell Immunotherapy against Melanoma: Clinical Trials Review. International Journal of Molecular Sciences, 2023, 24, 2413.	4.1	2
91	Predictive modeling of concentration-dependent viscosity behavior of monoclonal antibody solutions using artificial neural networks. MAbs, 2023, 15, .	5.2	5
93	Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?. Ophthalmic Plastic and Reconstructive Surgery, 2023, 39, 307-315.	0.8	1
94	Innovative strategies to study epigenetic regulation and advance precision medicine. , 2024, , 96-111.		0
95	Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging. , 2023, , 1-31.		0
96	Phenyldivinylsulfonamides for the construction of antibodyâ€“drug conjugates with controlled four payloads. Bioorganic Chemistry, 2023, 134, 106463.	4.1	3
97	Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction. Seminars in Cancer Biology, 2023, 91, 50-69.	9.6	10
98	Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis. Biotechnology Advances, 2023, 65, 108143.	11.7	4
99	Identification of Hetero-aggregates in Antibody Co-formulations by Multi-dimensional Liquid Chromatography Coupled to Mass Spectrometry. Analytical Chemistry, 2023, 95, 2203-2212.	6.5	3
100	The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation. International Immunopharmacology, 2023, 116, 109704.	3.8	0

#	Article	IF	Citations
101	A multiparameter optimization in middleâ€down analysis of monoclonal antibodies by LCâ€“MS/MS. Journal of Mass Spectrometry, 2023, 58, .	1.6	6
102	Benefits and Limitations of High-Resolution Cyclic IM-MS for Conformational Characterization of Native Therapeutic Monoclonal Antibodies. Analytical Chemistry, 2023, 95, 4162-4171.	6.5	3
103	Bioprocess Development and Characterization of a 13C-Labeled Hybrid Bispecific Antibody Produced in Escherichia coli. Antibodies, 2023, 12, 16.	2.5	2
104	Online Collision-Induced Unfolding of Therapeutic Monoclonal Antibody Glyco-Variants through Direct Hyphenation of Cation Exchange Chromatography with Native Ion Mobilityâ€“Mass Spectrometry. Analytical Chemistry, 2023, 95, 3932-3939.	6.5	5
105	Two-Dimensional Capillary Zone Electrophoresis-Mass Spectrometry: Intact mAb Charge Variant Separation Followed by Peptide Level Analysis Using In-Capillary Digestion. Analytical Chemistry, 2023, 95, 4059-4066.	6.5	6
106	Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma. Cancers, 2023, 15, 1366.	3.7	3
107	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. International Journal of Molecular Sciences, 2023, 24, 4401.	4.1	4
108	Pharmacogenetic Biomarkers of Protein Therapeutics. , 2023, , 233-249.		1
109	Nanoparticle Targeting with Antibodies in the Central Nervous System. BME Frontiers, 2023, 4, .	4.5	5
110	Backbone NMR assignment of the yeast expressed Fab fragment of the NISTmAb reference antibody. Biomolecular NMR Assignments, 0, , .	0.8	1
111	A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies. Biochemical Pharmacology, 2023, 210, 115470.	4.4	1
112	Effect of Fc core fucosylation and light chain isotype on IgG1 flexibility. Communications Biology, 2023, 6, .	4.4	0
114	Anti-epithelial-derived cytokines for severe asthma: Systematic review and meta-analysis. Journal of Allergy and Clinical Immunology, 2023, , .	2.9	0
115	Blueprint for antibody biologics developability. MAbs, 2023, 15, .	5.2	9
116	Diagnostic Flow Cytometry in the Era of Targeted Therapies. Surgical Pathology Clinics, 2023, 16, 423-431.	1.7	1
117	Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States. Expert Opinion on Biological Therapy, 2023, 23, 841-849.	3.1	1
118	Method for obtaining recombinant antibodies produced by a cell line transduced with recombinant adenoviruses. Fine Chemical Technologies, 2023, 18, 48-64.	0.8	0
119	Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells. Pharmaceutics, 2023, 15, 987.	4.5	1

#	Article	IF	Citations
120	Plant-based biopharmaceutical engineering. , 2023, 1, 426-439.		24
121	Impact of IgG subclass on monoclonal antibody developability. MAbs, 2023, 15, .	5.2	2
122	Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point. AAPS Journal, 2023, 25, .	4.4	4
123	Development and Validation of RPH-104 Quantification Method in Blood Serum as a Tool for Personalization of Pharmacotherapy. Pharmaceutical Chemistry Journal, 2023, 56, 1677-1681.	0.8	0
124	A novel brick for bispecific antibody construction. Proteins: Structure, Function and Bioinformatics, 0, , .	2.6	0
125	Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biology and Medicine, 2023, 20, 181-195.	3.0	10
126	Conjugated surfactant micelles: A nonâ€denaturing purification platform for concentrated human immunoglobulin G. Nano Select, 2023, 4, 386-394.	3.7	1
127	LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity. PLoS ONE, 2023, 18, e0282147.	2.5	2
128	Mutation of the <scp>TGN1412 antiâ€CD28</scp> monoclonal antibody lower hinge confers specific <scp>FcÎ³RIIb</scp> binding and retention of <scp>superâ€agonist</scp> activity. Immunology and Cell Biology, 2023, 101, 657-662.	2.3	1
129	Host cell protein quantification workflow using optimized standards combined with data-independent acquisition mass spectrometry. Journal of Pharmaceutical Analysis, 2023, 13, 494-502.	5.3	2
130	Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics. MAbs, 2023, 15, .	5.2	10
131	Surface patches induce nonspecific binding and phase separation of antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	3
132	Automated optimisation of solubility and conformational stability of antibodies and proteins. Nature Communications, 2023, 14, .	12.8	5
133	Exploring the Fate of Antibody-Encoding pDNA after Intramuscular Electroporation in Mice. Pharmaceutics, 2023, 15, 1160.	4.5	1
134	Predictive Nature of High-Throughput Assays in ADC Formulation Screening. Journal of Pharmaceutical Sciences, 2023, , .	3.3	0
135	Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy. Strahlentherapie Und Onkologie, 2023, 199, 1091-1109.	2.0	3
137	Progress in Top-Down LC-MS Analysis of Antibodies: Review. Biotechnology and Bioprocess Engineering, 2023, 28, 226-233.	2.6	0
139	High concentration formulation developability approaches and considerations. MAbs, 2023, 15, .	5.2	8

#	Article	IF	Citations
140	Fluorescence coupling strategies in fluorescence-activated droplet sorting (FADS) for ultrahigh-throughput screening of enzymes, metabolites, and antibodies. Biotechnology Advances, 2023, 66, 108173.	11.7	3
143	Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	0
144	Mapping time dependent disulfide bond formation during in-vitro refolding of recombinant peptibody: A Fc-fusion protein. Biochemical Engineering Journal, 2023, 197, 108969.	3.6	0
145	Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies. Life, 2023, 13, 1272.	2.4	0
146	ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins. Communications Biology, 2023, 6, .	4.4	40
147	Multi-omics for COVID-19: driving development of therapeutics and vaccines. National Science Review, 2023, 10, .	9.5	2
148	Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeutics. Biotechnology Advances, 2023, 67, 108192.	11.7	0
149	Plant glycoengineering for designing next-generation vaccines and therapeutic proteins. Biotechnology Advances, 2023, 67, 108197.	11.7	7
150	Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies. MAbs, 2023, 15, .	5.2	1
151	Efficient separation of IgG from IgM antibodies via conjugated surfactant micelles. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2023, 1226, 123805.	2.3	0
152	Structural pre-training improves physical accuracy of antibody structure prediction using deep learning.. ImmunoInformatics, 2023, , 100028.	2.2	0
154	Selfâ€Immolative Nanobodyâ€Cysteine Residue Modification for Controlled Immunodrug Delivery. Advanced Therapeutics, 0, , .	3.2	1
155	VERITAS: Harnessing the power of nomenclature in biologic discovery. MAbs, 2023, 15, .	5.2	0
156	The Dawn of a New Era: Targeting the â€œUndruggablesâ€•with Antibody-Based Therapeutics. Chemical Reviews, 2023, 123, 7782-7853.	47.7	13
157	Use of single analytic tool to quantify both absolute Nâ€glycosylation and glycan distribution in monoclonal antibodies. Biotechnology Progress, 2023, 39, .	2.6	1
158	A mammalian cell display platform based on scFab transposition. Antibody Therapeutics, 2023, 6, 157-169.	1.9	0
159	Transferrin receptor-targeting property of pabinafusp alfa facilitates its uptake by various types of human brain-derived cells in vitro. Frontiers in Drug Delivery, 0, 3, .	1.6	0
160	Facile One-Step Generation of Camelid VHH and Avian scFv Libraries for Phage Display by Golden Gate Cloning. Methods in Molecular Biology, 2023, , 47-60.	0.9	0

#	Article	IF	Citations
161	Bulk Reformatting of Antibody Fragments Displayed on the Surface of Yeast Cells to Final IgG Format for Mammalian Production. Methods in Molecular Biology, 2023, , 291-311.	0.9	0
162	Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy. Nature Immunology, 2023, 24, 1244-1255.	14.5	10
163	Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study. Annals of Medicine, 2023, 55, .	3.8	3
164	Concentrationâ€dependent diffusion of unlabeled protein within an in vitro hyaluronic acid matrix. Biotechnology and Bioengineering, 0, , .	3.3	0
165	Monitoring mAb proteoforms in mouse plasma using an automated immunocapture combined with topâ€down and middleâ€down mass spectrometry. Proteomics, 2024, 24, .	2.2	1
166	Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer Treatments. BioDrugs, 0, , .	4.6	0
167	Ssa1-targeted antibody prevents host invasion by Candida albicans. Frontiers in Microbiology, 0, 14, .	3.5	2
168	Multi-Attribute Method (MAM): An Emerging Analytical Workflow for Biopharmaceutical Characterization, Batch Release and cGMP Purity Testing at the Peptide and Intact Protein Level. Critical Reviews in Analytical Chemistry, 0, , 1-18.	3.5	4
169	KA-Search, a method for rapid and exhaustive sequence identity search of known antibodies. Scientific Reports, 2023, 13, .	3.3	2
170	Phage-derived anti-idiotype and anti-YTE antibodies in development of MK-1654 pharmacokinetic and immune response assays. Bioanalysis, 2023, 15, 1049-1067.	1.5	1
171	Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Medicine (United States), 2023, 102, e34516.	1.0	1
172	How can we discover developable antibody-based biotherapeutics?. Frontiers in Molecular Biosciences, 0, 10, .	3.5	3
173	Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia. Bioengineered, 2023, 14, .	3.2	1
174	High throughput purification of monoclonal recombinant antibodies using a Protein-A coated membrane plate system. New Biotechnology, 2023, 77, 111-119.	4.4	0
175	Diplomate in Medical Laboratory Immunology Certification Examination: A New Chapter for Medical Laboratory Immunology. ImmunoHorizons, 2023, 7, 600-610.	1.8	0
176	Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing. Melanoma Research, 0, , .	1.2	1
177	Expanding the Analytical Toolbox: Developing New Lys-C Peptide Mapping Methods with Minimized Assay-Induced Artifacts to Fully Characterize Antibodies. Pharmaceuticals, 2023, 16, 1327.	3.8	0
178	Computational Methods in Immunology and Vaccinology: Design and Development of Antibodies and Immunogens. Journal of Chemical Theory and Computation, 2023, 19, 5315-5333.	5.3	3

#	Article	IF	Citations
179	Functional integration of protein A binding ability to antibody fragments for convenient and tag-free purification. Bioengineered, 2023, 14, .	3.2	0
180	Nanoconjugate formulations for enhanced drug delivery. , 2023, , 441-491.		1
181	Selection of bispecific antibodies with optimal developability using FcRnâ€'pHâ€'HPLC as an optimized FcRn affinity chromatography method. MAbs, 2023, 15, .	5.2	2
182	Construction of Synthetic Antibody Phage Display Libraries. Methods in Molecular Biology, 2023, , 59-75.	0.9	0
183	Evaluation of Tetrazine Tracers for Pretargeted Imaging within the Central Nervous System. Bioconjugate Chemistry, 2023, 34, 1882-1893.	3.6	1
184	The origins of nonideality exhibited by monoclonal antibodies and <scp>Fab</scp> fragments in human serum. Protein Science, 2023, 32, .	7.6	0
185	<scp>QTY</scp> code designed antibodies for aggregation prevention: A structural bioinformatic and computational study. Proteins: Structure, Function and Bioinformatics, 2024, 92, 206-218.	2.6	1
186	The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials. Medicine (United States), 2023, 102, e34746.	1.0	0
187	Development of a concise and reliable method for quantifying the antibody loaded onto lipid nanoparticles modified with Herceptin. Journal of Immunological Methods, 2023, 521, 113554.	1.4	1
188	Construction of Human Immune and Naive scFv Phage Display Libraries. Methods in Molecular Biology, 2023, , 15-37.	0.9	0
189	Antibody Batch Cloning. Methods in Molecular Biology, 2023, , 411-417.	0.9	0
190	Developing a flowchart to evaluate the use of Closed System Drug-Transfer Devices with monoclonal antibodies: Focus on the clinical trial setting. Journal of Oncology Pharmacy Practice, 2023, 29, 2014-2022.	0.9	1
191	An engineered bispecific nanobody in tetrameric secretory IgA format confers broad neutralization against SARS-CoV-1&2 and most variants. International Journal of Biological Macromolecules, 2023, 253, 126817.	7.5	0
192	Attenuated effects of topical vinpocetine in an imiquimod-induced mouse model of psoriasis. Journal of Taibah University Medical Sciences, 2024, 19, 35-53.	0.9	1
193	Benchmarking TriadAb using targets from the second antibody modeling assessment. Protein Engineering, Design and Selection, 2023, 36, .	2.1	1
194	Development of a Cytotoxic Antibodyâ€"Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells. International Journal of Molecular Sciences, 2023, 24, 14997.	4.1	0
196	Structure and Dynamics Guiding Design of Antibody Therapeutics and Vaccines. Antibodies, 2023, 12, 67.	2.5	0
197	Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20. Scientific Reports, 2023, 13, .	3.3	0

#	Article	IF	Citations
198	Exploring a Role for Flow-Induced Aggregation Assays in Platform Formulation Optimisation for Antibody-Based Proteins. Journal of Pharmaceutical Sciences, 2024, 113, 625-636.	3.3	0
199	A Clinical Viewpoint on the Use of Targeted Therapy in Advanced Gastric Cancer. Cancers, 2023, 15, 5490.	3.7	1
200	Improved characterization of trastuzumab deruxtecan with PTCR and internal fragments implemented in middle-down MS workflows. Analytical and Bioanalytical Chemistry, 2024, 416, 519-532.	3.7	1
201	Characterization of Higher Order Structural Changes of a Thermally Stressed Monoclonal Antibody via Mass Spectrometry Footprinting and Other Biophysical Approaches. Analytical Chemistry, 2023, 95, 16840-16849.	6.5	1
202	PEP-Patch: Electrostatics in Proteinâ€"Protein Recognition, Specificity, and Antibody Developability. Journal of Chemical Information and Modeling, 2023, 63, 6964-6971.	5.4	0
203	Phage display assisted discovery of a <scp>pH</scp>â€dependent antiâ€Î±â€cobratoxin antibody from a natural variable domain library. Protein Science, 2023, 32, .	7.6	1
204	Basic Regulatory Science Behind Drug Substance and Drug Product Specifications of Monoclonal Antibodies and Other Protein Therapeutics. Journal of Pharmaceutical Analysis, 2023, , .	5.3	0
205	LCâ€"MS Approach to Decipher a Light Chain Chromatographic Peak Splitting of a Monoclonal Antibody. Pharmaceutical Research, 2023, 40, 3087-3098.	3.5	0
206	Application of Raman Spectroscopy to Dynamic Binding Capacity Analysis. Applied Spectroscopy, 2023, 77, 1393-1400.	2.2	0
207	Three-Dimensional Homodyne Light Detection (3D-HLD) for High-Throughput Submicron Particle Analysis in (Highly Concentrated) Protein Biopharmaceuticals, Viral Vectors, and LNPs. Journal of Pharmaceutical Sciences, 2023, , .	3.3	0
208	Process intensification in biopharmaceutical process development and productionÂâ€" an industrial perspective. ChemistrySelect, 2023, .	1.5	1
209	The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus. Animal Diseases, 2023, 3, .	1.4	0
210	Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets. MAbs, 2023, 15, .	5.2	0
211	Reprogramming Megakaryocytes for Controlled Release of Platelet-like Particles Carrying a Single-Chain Thromboxane A2 Receptor-G-Protein Complex with Therapeutic Potential. Cells, 2023, 12, 2775.	4.1	0
212	Isolation and characterization of a novel single-chain variable fragment (scFv) against Lymphocyte function-associated antigen-1 (LFA-1) using phage display method. , 2024, 41, .		0
214	Therapeutic Monoclonal Antibodies against Cancer: Present and Future. Cells, 2023, 12, 2837.	4.1	1
215	Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives. Frontiers in Oncology, 0, 13, .	2.8	0
216	Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS. Pathogens, 2024, 13, 14.	2.8	0

#	Article	IF	Citations
217	Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond. Journal of Gastric Cancer, 0, 24, .	2.5	1
218	Antibodies, repertoires and microdevices in antibody discovery and characterization. Lab on A Chip, 2024, 24, 1207-1225.	6.0	0
219	Teaching biologics design using molecular modeling and simulations. Biochemistry and Molecular Biology Education, 0, , .	1.2	0
220	Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies. Cureus, 2024, , .	0.5	0
221	ProtT5 and random forests-based viscosity prediction method for therapeutic mAbs. European Journal of Pharmaceutical Sciences, 2024, 194, 106705.	4.0	0
222	Stabilization of adalimumab Fab through the introduction of disulfide bonds between the variable and constant domains. Biochemical and Biophysical Research Communications, 2024, 700, 149592.	2.1	0
223	SEC-MS in denaturing conditions (dSEC-MS) for in-depth analysis of rebridged monoclonal antibody-based formats. Talanta, 2024, 272, 125727.	5.5	0
224	Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022. Current Pharmacology Reports, 2024, 10, 96-120.	3.0	0
225	An integrated methodology for quality assessment of therapeutic antibodies with potential long circulation half-life in harvested cell culture fluid using FcRn immobilized hydrophilic magnetic graphene. Talanta, 2024, 272, 125781.	5.5	0
226	Discovery of broadlyâ€neutralizing antibodies against brown recluse spider and Gadim scorpion sphingomyelinases using consensus toxins as antigens. Protein Science, 2024, 33, .	7.6	0
227	Preclinical Development of Monoclonal Antibodies. , 2024, , 637-669.		0
228	The role of viruses in oral mucosal lesions. Periodontology 2000, 0, , .	13.4	0
229	Streamlined Multi-Attribute Assessment of an Array of Clinical-Stage Antibodies: Relationship Between Degradation and Stability. Applied Spectroscopy, 0, , .	2.2	0
230	Ameliorative effects of topical ramelteon on imiquimod-induced psoriasiform inflammation in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 0, , .	3.0	0
231	Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies. MAbs, 2024, 16, .	5.2	0
232	Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nature Communications, 2024, 15, .	12.8	0
233	Unleashing the power of antibodies: Engineering for tomorrowâ€™s therapy. Advances in Protein Chemistry and Structural Biology, 2024, , .	2.3	0
234	A Novel 3D-Printed and Miniaturized Periodic Counter Current Chromatography System for Continuous Purification of Monoclonal Antibodies. Micromachines, 2024, 15, 382.	2.9	0

#	Article	IF	Citations
235	Camel-Derived Nanobodies as Potent Inhibitors of New Delhi Metallo-Î²-Lactamase-1 Enzyme. Molecules, 2024, 29, 1431.	3.8	0
236	A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic. Pharmaceutical Research, 2024, 41, 651-672.	3.5	0
237	Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins. Frontiers in Immunology, 0, 15, .	4.8	0
238	When will we have a clone? An industry perspective on the typical <scp>CLD</scp> timeline. Biotechnology Progress, 0, , .	2.6	0
239	How spray drying processing and solution composition can affect the mAbs stability in reconstituted solutions for subcutaneous injections. Part II: Exploring each protein stabilizer effect. International Journal of Pharmaceutics, 2024, 655, 124014.	5.2	0